2023 Predictions – the Good, the Bad, and the Ugly
Using Computational Disease Models and Synthetic Clinical Trials for Drug Research and Development with David Harel CytoReason
Executives Reunite at JPM as Biotech Kicks Off 2023
The Rise of Computational Biology in Biopharma
Pfizer Deepens Investment in CytoReason for Novel Drug Discovery and Development
Company of the Year 2022: Pfizer – Building on Covid-19
Follow the Money: NIH Funds Brain Mapping Network Initiative, Non-Invasive Skin Patch for Vaccine Delivery, More
CytoReason and Pfizer extend their alliance for AI delivery in drug discovery
Pfizer strengthens AI drug discovery collaboration with equity investment
Pfizer Extends Collaboration With Disease Model Co CytoReason
